NextCure (NXTC) Share-based Compensation (2018 - 2026)
NextCure (NXTC) posted quarterly Share-based Compensation of $2.5 million for Q1 2026, up 83.42% year-over-year from $1.4 million in Q1 2025, and up 456.79% quarter-over-quarter from $449000.0 in Q4 2025.
NextCure (NXTC) Share-based Compensation (2018 - 2026) Analysis & Trends
NextCure's Share-based Compensation history runs 9 years deep, the most recent figure standing at $2.5 million for Q1 2026.
- In Q1 2026, Share-based Compensation rose 83.42% year-over-year to $2.5 million; the TTM figure through Mar 2026 stood at $2.5 million (down 58.37% YoY), while the FY2025 annual figure was $3.0 million, down 52.64% from the prior year.
- Share-based Compensation for Q1 2026 stood at $2.5 million, up from $449000.0 in the prior quarter.
- The five-year high for Share-based Compensation was $2.6 million in Q1 2022, with the low at $449000.0 in Q4 2025.
- The 5-year median for Share-based Compensation is $2.0 million (2023), against an average of $1.7 million.
- The sharpest annual moves came in 2025 and 2026: Share-based Compensation plunged 70.44% in 2025, then soared 83.42% in 2026.
- NextCure's Share-based Compensation stood at $2.3 million in 2022, then decreased by 13.89% to $2.0 million in 2023, then declined by 23.9% to $1.5 million in 2024, then slumped by 70.44% to $449000.0 in 2025, then surged by 456.79% to $2.5 million in 2026.
- Business Quant data shows NXTC's Share-based Compensation at $2.5 million in Q1 2026, $449000.0 in Q4 2025, and $600000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | NextCure | 33.72 Mn | 33.72 Mn | - | 2.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.30 Mn |
| Jun 30, 2026 | 2.30 Mn |
| Mar 31, 2026 | 2.50 Mn |
| Mar 31, 2026 | 2.50 Mn |
| Dec 31, 2025 | 449,000.00 |
| Dec 31, 2025 | 449,000.00 |
| Sep 30, 2025 | 600,000.00 |
| Sep 30, 2025 | 600,000.00 |
| Jun 30, 2025 | 587,000.00 |
| Jun 30, 2025 | 587,000.00 |
| Mar 31, 2025 | 1.36 Mn |
| Mar 31, 2025 | 1.36 Mn |
| Dec 31, 2024 | 1.52 Mn |
| Dec 31, 2024 | 1.52 Mn |
| Sep 30, 2024 | 1.53 Mn |
| Sep 30, 2024 | 1.53 Mn |
| Jun 30, 2024 | 1.59 Mn |
| Jun 30, 2024 | 1.59 Mn |
| Mar 31, 2024 | 1.69 Mn |
| Mar 31, 2024 | 1.69 Mn |